Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Current and future treatment strategies for type 2 diabetes: the beta-cell as a therapeutic target.

Tyrberg B, Levine F.

Curr Opin Investig Drugs. 2001 Nov;2(11):1568-74. Review.

PMID:
11763159
2.

Targeting beta-cell cyclic 3'5' adenosine monophosphate for the development of novel drugs for treating type 2 diabetes mellitus. A review.

Furman B, Pyne N, Flatt P, O'Harte F.

J Pharm Pharmacol. 2004 Dec;56(12):1477-92. Review.

PMID:
15563754
3.

Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes.

Ahrén B.

Nat Rev Drug Discov. 2009 May;8(5):369-85. doi: 10.1038/nrd2782. Epub 2009 Apr 14. Review. Erratum in: Nat Rev Drug Discov. 2009 Aug;8(8):626. Nat Rev Drug Discov. 2009 Jun;8(6):516.

PMID:
19365392
4.
5.

Fate of the beta-cell in the pathophysiology of type 2 diabetes.

Campbell RK.

J Am Pharm Assoc (2003). 2009 Sep-Oct;49 Suppl 1:S10-5. doi: 10.1331/JAPhA.2009.09076. Review.

PMID:
19801360
6.

Glucagon like peptides-1 modulators as newer target for diabetes.

Vaidya HB, Goyal RK.

Curr Drug Targets. 2008 Oct;9(10):911-20. Review.

PMID:
18855626
7.
8.

Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.

Mu J, Woods J, Zhou YP, Roy RS, Li Z, Zycband E, Feng Y, Zhu L, Li C, Howard AD, Moller DE, Thornberry NA, Zhang BB.

Diabetes. 2006 Jun;55(6):1695-704.

9.
10.

Sulfonylurea treatment of type 2 diabetes mellitus: focus on glimepiride.

Korytkowski MT.

Pharmacotherapy. 2004 May;24(5):606-20. Review.

PMID:
15162895
11.

Pharmacological interventions that directly stimulate or modulate insulin secretion from pancreatic beta-cell: implications for the treatment of type 2 diabetes.

Farret A, Lugo-Garcia L, Galtier F, Gross R, Petit P.

Fundam Clin Pharmacol. 2005 Dec;19(6):647-56. Review.

PMID:
16313276
12.

Oral antidiabetic agents: current role in type 2 diabetes mellitus.

Krentz AJ, Bailey CJ.

Drugs. 2005;65(3):385-411. Review.

PMID:
15669880
13.

Insulin sensitisation in the treatment of Type 2 diabetes.

Tadayyon M, Smith SA.

Expert Opin Investig Drugs. 2003 Mar;12(3):307-24. Review.

PMID:
12605557
14.

Metformin plus low-dose glimeperide significantly improves Homeostasis Model Assessment for insulin resistance (HOMA(IR)) and beta-cell function (HOMA(beta-cell)) without hyperinsulinemia in patients with type 2 diabetes mellitus.

Bermúdez-Pirela VJ, Cano C, Medina MT, Souki A, Lemus MA, Leal EM, Seyfi HA, Cano R, Ciscek A, Bermúdez-Arias F, Contreras F, Israili ZH, Hernández-Hernández R, Valasco M.

Am J Ther. 2007 Mar-Apr;14(2):194-202.

PMID:
17414590
15.

Protection of pancreatic beta-cells: is it feasible?

Bonora E.

Nutr Metab Cardiovasc Dis. 2008 Jan;18(1):74-83. Review.

PMID:
18096375
16.

Improvement of metabolic state in an animal model of nutrition-dependent type 2 diabetes following treatment with S 23521, a new glucagon-like peptide 1 (GLP-1) analogue.

Uçkaya G, Delagrange P, Chavanieu A, Grassy G, Berthault MF, Ktorza A, Cerasi E, Leibowitz G, Kaiser N.

J Endocrinol. 2005 Mar;184(3):505-13.

17.

The place of sulfonylureas in the therapy for type 2 diabetes mellitus.

Del Prato S, Pulizzi N.

Metabolism. 2006 May;55(5 Suppl 1):S20-7. Review.

PMID:
16631807
18.

Beta-cell response to intravenous glucagon in African-American and Hispanic children with type 2 diabetes mellitus.

Taha DR, Castells S, Umpaichitra V, Bastian W, Banerji MA.

J Pediatr Endocrinol Metab. 2002 Jan;15(1):59-67.

PMID:
11822582
19.

Can thiazolidinediones delay disease progression in type 2 diabetes?

Leiter LA.

Curr Med Res Opin. 2006 Jun;22(6):1193-201. Review.

PMID:
16846552
20.

Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.

Pratley RE, Salsali A.

Curr Med Res Opin. 2007 Apr;23(4):919-31. Review.

PMID:
17407649
Items per page

Supplemental Content

Write to the Help Desk